Profile data is unavailable for this security.
About the company
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
- Revenue in USD (TTM)0.00
- Net income in USD-75.88m
- Incorporated2021
- Employees105.00
- LocationBarinthus Biotherapeutics PLCThe Schrdinger BuildingHeatley Road, The Oxford Science ParkDIDCOT OX11 0DFUnited KingdomGBR
- Phone+44 186 581 8808
- Websitehttps://www.barinthusbio.com/
More ▼
Mergers & acquisitions
| Acquired company | 2AB:FRA since announced | Transaction value |
|---|---|---|
| Clywedog Therapeutics Inc | -50.10% | -- |
Data delayed at least 15 minutes, as of Feb 18 2026 07:01 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspira Women's Health Inc | 9.34m | -10.80m | 22.61m | 66.00 | -- | -- | -- | 2.42 | -0.3782 | -0.3782 | 0.3387 | -0.1018 | 1.55 | 11.79 | 7.26 | 141,469.70 | -179.16 | -116.24 | -903.68 | -168.65 | 63.90 | 50.98 | -115.66 | -287.59 | 1.32 | -189.81 | -- | -- | 0.3059 | 15.14 | 21.55 | -- | -22.58 | -- |
| Rallybio Corp | 674.00k | -14.17m | 22.86m | 15.00 | -- | 0.3601 | -- | 33.92 | -2.55 | -2.55 | 0.1203 | 12.02 | 0.0092 | -- | -- | 26,960.00 | -19.32 | -40.97 | -21.16 | -43.42 | -- | -- | -2,102.37 | -42,838.52 | -- | -- | 0.00 | -- | -- | -- | 22.52 | -- | -- | -- |
| Cue Biopharma Inc | 7.10m | -37.68m | 22.92m | 41.00 | -- | 1.71 | -- | 3.23 | -0.4553 | -0.4553 | 0.0823 | 0.1703 | 0.1857 | -- | 4.01 | 173,170.70 | -98.58 | -60.20 | -170.74 | -73.56 | -- | -- | -530.75 | -683.99 | -- | -- | 0.1107 | -- | 69.16 | 21.84 | 19.83 | -- | 7.32 | -- |
| LAMY | 0.00 | 106.70k | 23.10m | -- | 24.05 | -- | 190.26 | -- | 0.0137 | 0.0137 | 0.00 | -0.0045 | 0.00 | -- | -- | -- | 763.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -67.39 | -- | 299.15 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -3.00k | 23.30m | 5.00 | 0.1992 | -- | 298.76 | -- | 4.87 | 4.87 | 0.00 | -1.71 | 0.00 | -- | -- | 0.00 | -0.0471 | -- | -- | -- | -- | -- | -- | -- | -- | -5.95 | -- | -- | -- | -- | 110.92 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -51.23m | 23.72m | -- | -- | 0.6984 | -- | -- | -1.29 | -1.29 | 0.00 | 1.06 | 0.00 | -- | -- | -- | -83.39 | -139.20 | -94.11 | -262.81 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.43 | -- | -- | -- |
| Marker Therapeutics Inc | 4.69m | -14.30m | 24.18m | 5.00 | -- | 1.32 | -- | 5.15 | -1.23 | -1.23 | 0.3683 | 1.10 | 0.2876 | -- | 3.90 | 938,996.00 | -87.60 | -57.72 | -110.67 | -69.11 | -- | -- | -304.54 | -761.28 | -- | -- | 0.00 | -- | 99.06 | 98.63 | 23.60 | -- | -- | -- |
| IGC Pharma Inc | 1.11m | -6.45m | 24.53m | 70.00 | -- | 2.91 | -- | 22.18 | -0.078 | -0.078 | 0.0134 | 0.088 | 0.11 | 0.5489 | 26.02 | 15,800.00 | -64.10 | -51.04 | -81.62 | -56.88 | 46.20 | 43.57 | -582.82 | -1,150.02 | 0.889 | -- | 0.0165 | -- | -5.50 | -20.77 | 45.22 | -- | -35.93 | -- |
| Exicure Inc | 0.00 | -9.23m | 24.76m | 8.00 | -- | 3.57 | -- | -- | -3.07 | -3.07 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -71.27 | -44.45 | -94.78 | -60.08 | -- | -- | -- | -259.52 | -- | -- | 0.00 | -- | -- | -17.34 | 42.65 | -- | -- | -- |
| Evaxion A/S (ADR) | 7.65m | -5.42m | 25.04m | 46.00 | -- | -- | -- | 3.27 | -16.88 | -16.88 | 2.18 | -- | -- | -- | -- | 166,326.10 | -- | -96.54 | -- | -126.06 | -- | -- | -70.88 | -2,792.25 | -- | -- | -- | -- | 4,480.82 | -- | 52.24 | -- | -- | -- |
| Barinthus Biotherapeutics PLC - ADR | 0.00 | -75.88m | 25.07m | 105.00 | -- | 0.2968 | -- | -- | -1.88 | -1.88 | 0.00 | 2.07 | 0.00 | -- | -- | 0.00 | -50.99 | -21.90 | -55.89 | -23.34 | -- | -- | -- | -302.54 | -- | -- | 0.00 | -- | 1,766.46 | 16.94 | 16.73 | -- | 47.49 | -- |
| Boundless Bio Inc | 0.00 | -61.76m | 25.74m | 64.00 | -- | 0.2337 | -- | -- | -16.06 | -16.06 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -35.93 | -- | -38.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.22 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.35m | 26.33m | 80.00 | -- | 28.00 | -- | -- | -1.34 | -1.34 | 0.00 | 0.0131 | 0.00 | -- | -- | 0.00 | -136.03 | -58.51 | -184.96 | -64.76 | -- | -- | -- | -- | -- | -- | 0.9482 | -- | -- | -- | -10.93 | -- | -- | -- |
| VolitionRX Ltd | 1.47m | -22.88m | 27.27m | 85.00 | -- | -- | -- | 18.53 | -0.229 | -0.229 | 0.0147 | -0.316 | 0.1539 | -- | 4.74 | 17,317.88 | -241.07 | -122.29 | -- | -283.19 | -- | -- | -1,566.40 | -5,826.45 | -- | -15.03 | -- | -- | 59.10 | 135.30 | 23.65 | -- | 2.34 | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 27.48m | 0.00 | -- | -- | -- | -- | -0.0723 | -0.0723 | 0.00 | -0.0644 | 0.00 | -- | -- | -- | -4,831.04 | -- | -- | -- | -- | -- | -- | -- | -- | -86.56 | -- | -- | -- | -- | -13.02 | -- | -- | -- |
Data as of Feb 18 2026. Currency figures normalised to Barinthus Biotherapeutics PLC's reporting currency: US Dollar USD
15.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 31 Dec 2025 | 5.20m | 12.73% |
| DC Investments Management LLCas of 31 Dec 2025 | 642.20k | 1.57% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 143.10k | 0.35% |
| The Johns Hopkins University (Investment Management)as of 30 Sep 2025 | 122.24k | 0.30% |
| Robert W. Baird & Co., Inc. (Private Banking)as of 31 Dec 2025 | 105.96k | 0.26% |
| Hightower Advisors LLCas of 31 Dec 2025 | 37.45k | 0.09% |
| XTX Markets LLCas of 30 Sep 2025 | 13.01k | 0.03% |
| RhumbLine Advisers LPas of 31 Dec 2025 | 11.69k | 0.03% |
| Geode Capital Management LLCas of 31 Dec 2025 | 11.57k | 0.03% |
| UBS Securities LLCas of 31 Dec 2025 | 3.15k | 0.01% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
